P. Sanchez

发表

Leveraging preclinical models for the development of Alzheimer disease therapeutics

K. Scearce-Levie, Pascal E. Sanchez, Joseph W. Lewcock, 2020, Nature Reviews Drug Discovery.

Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice

Adam P. Silverman, Jennifer A. Getz, Michelle L. Reyzer, 2020, Science Translational Medicine.

Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic

Katrina W. Lexa, B. Boeve, H. Rosen, 2021, Cell.

Targeting Transferrin Receptor to Transport Antisense Oligonucleotides Across the Blood-Brain Barrier

K. Gadkar, T. Sandmann, C. Koth, 2023, bioRxiv.

A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models

Nicholas E. Propson, K. Scearce-Levie, Steve Lianoglou, 2023, Nature Neuroscience.

Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys

Adam P. Silverman, Jennifer A. Getz, T. Miyamoto, 2020, Science Translational Medicine.

TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge

Steve Lianoglou, T. Sandmann, S. Poda, 2019, Neuron.

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome

T. Gill, K. Scearce-Levie, Elliot R. Thomsen, 2021, JCI insight.

Molecular architecture determines brain delivery of a transferrin receptor–targeted lysosomal enzyme

K. Scearce-Levie, K. Gunasekaran, L. Shan, 2021, bioRxiv.

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia

Julie A. Harris, Jennifer D. Whitesell, K. Scearce-Levie, 2022, Molecular neurodegeneration.

Leveraging preclinical models for the development of Alzheimer disease therapeutics

K. Scearce-Levie, Pascal E. Sanchez, Joseph W. Lewcock, 2020, Nature Reviews Drug Discovery.

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model

Keith A. Vossel, K. Vossel, L. Mucke, 2012, Proceedings of the National Academy of Sciences.

Cross-species translation of the Morris maze for Alzheimer's disease.

Geoffrey A Kerchner, Steven Finkbeiner, Clifford Anderson-Bergman, 2016, The Journal of clinical investigation.

Life Extension Factor Klotho Prevents Mortality and Enhances Cognition in hAPP Transgenic Mice

L. Mucke, E. Masliah, M. Kuro-o, 2015, The Journal of Neuroscience.

Network dysfunction in α‐synuclein transgenic mice and human Lewy body dementia

Meaghan Morris, K. Vossel, L. Mucke, 2015, Annals of clinical and translational neurology.

Physiological Brain Activity Causes DNA Double Strand Breaks in Neurons — Exacerbation by Amyloid-β

Anatol C. Kreitzer, Alexxai V. Kravitz, A. Kreitzer, 2013, Nature Neuroscience.

Ablation of Cellular Prion Protein Does Not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice

L. Mucke, M. Cissé, Kaitlyn Ho, 2011, The Journal of Neuroscience.

Standardized Environmental Enrichment Supports Enhanced Brain Plasticity in Healthy Rats and Prevents Cognitive Impairment in Epileptic Rats

R. S. Sloviter, A. Belmeguenai, J. Bodennec, 2013, PloS one.

Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1

L. Mucke, J. Paz, J. Palop, 2020, Molecular Neurodegeneration.

Brain heparanase expression is up‐regulated during postnatal development and hypoxia‐induced neovascularization in adult rats

A. Morales, L. Bezin, Pascal E. Sanchez, 2008, Journal of neurochemistry.

Erythropoietin receptor expression is concordant with erythropoietin but not with common β chain expression in the rat brain throughout the life span

P. Ryvlin, A. Belmeguenai, J. Bodennec, 2009, The Journal of comparative neurology.

Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons

R. Levine, A. Belmeguenai, E. Baulieu, 2009, Proceedings of the National Academy of Sciences.

Tau Reduction Prevents Disease in a Mouse Model of Dravet Syndrome

L. Mucke, M. Finucane, R. Ponnusamy, 2014, Annals of neurology.

Fibrillar Aβ causes profound microglial metabolic perturbations in a novel APP knock-in mouse model

Julie A. Harris, Jennifer D. Whitesell, K. Scearce-Levie, 2021, bioRxiv.

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

R. Maciuca, K. Scearce-Levie, Y. Ran, 2023, bioRxiv.

Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus

P. Ryvlin, A. Morales, L. Bezin, 2007, Neurobiology of Disease.

Brain heparanase expression is up‐regulated during postnatal development and hypoxia‐induced neovascularization in adult rats

A. Morales, L. Bezin, J. Pequignot, 2008, Journal of neurochemistry.

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

R. Maciuca, K. Scearce-Levie, Y. Ran, 2024, bioRxiv.